Ovid Therapeutics Inc. (OVID) Reaches $11.12 After 3.00% Down Move; CEBU AIR (CEBUF) Shorts Increased By 200%

December 1, 2017 - By mmahotstuff

CEBU AIR (OTCMKTS:CEBUF) had an increase of 200% in short interest. CEBUF’s SI was 300 shares in December as released by FINRA. Its up 200% from 100 shares previously. With 100 avg volume, 3 days are for CEBU AIR (OTCMKTS:CEBUF)’s short sellers to cover CEBUF’s short positions. It closed at $2.1 lastly. It is down 0.00% since December 1, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock of Ovid Therapeutics Inc. (NASDAQ:OVID) is a huge mover today! The stock decreased 9.67% or $1.19 during the last trading session, reaching $11.12. About 73,066 shares traded or 39.88% up from the average. Ovid Therapeutics Inc. (NASDAQ:OVID) has 0.00% since December 1, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 6 months negative chart setup for the $273.59M company. It was reported on Dec, 1 by Barchart.com. We have $10.79 PT which if reached, will make NASDAQ:OVID worth $8.21 million less.

Cebu Air, Inc. operates an airline under the Cebu Pacific Air name in the Philippines. The company has market cap of $1.27 billion. It offers scheduled air travel services to passengers, as well as airport-to-airport cargo services on its domestic and international routes. It has a 10.05 P/E ratio. The firm also provides ancillary services, such as cancellation and rebooking options; in-flight merchandising, including sale of duty-free products on international flights; baggage services; and travel-related services and products.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company has market cap of $273.59 million. The firm is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome. It currently has negative earnings. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting.

Analysts await Ovid Therapeutics Inc. (NASDAQ:OVID) to report earnings on February, 8. After $-0.38 actual EPS reported by Ovid Therapeutics Inc. for the previous quarter, Wall Street now forecasts 97.37% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>